Altamira Therapeutics (CYTO) Institutional Ownership → 1970’s computer coder Issues Shocking AI Warning (From InvestorPlace) (Ad) Free CYTO Stock Alerts $1.48 +0.01 (+0.68%) (As of 02:29 PM ET) Add Compare Share Share OwnershipStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Altamira Therapeutics (NASDAQ:CYTO)CurrentInstitutional OwnershipPercentage1.91%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$4.05MNumber ofInstitutional Sellers(last 12 months)0 Get CYTO Insider Trade Alerts Want to know when executives and insiders are buying or selling Altamira Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CYTO Institutional Buying and Selling by Quarter Ad Gold Safe ExchangeGold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! Altamira Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/15/2023Armistice Capital LLC829,000$203K0.0%N/A11.860% 11/7/2022Virtu Financial LLC124,787$36K0.0%+866.8%16.683% 8/12/2022Ikarian Capital LLC75,000$36K0.0%-76.6%0.501% 11/9/2021BlackRock Inc.32,592$65K0.0%N/A0.285% (Data available from 1/1/2016 forward) CYTO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CYTO shares? During the previous two years, the following institutional investors and hedge funds held shares of Altamira Therapeutics shares: Armistice Capital LLC ($203K), and Virtu Financial LLC ($36K), Ikarian Capital LLC ($36K).Learn more on CYTO's institutional investors. What percentage of Altamira Therapeutics stock is owned by institutional investors? 1.91% of Altamira Therapeutics stock is owned by institutional investors. Learn more on CYTO's institutional investor holdings. Which institutional investors have been buying Altamira Therapeutics stock? The following institutional investors have purchased Altamira Therapeutics stock in the last 24 months: Armistice Capital LLC ($829K), and Virtu Financial LLC ($111.88K). How much institutional buying is happening at Altamira Therapeutics? Institutional investors have bought a total of 940,880 shares in the last 24 months. This purchase volume represents approximately $17.03M in transactions. Which Altamira Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Altamira Therapeutics stock in the last 24 months: Ikarian Capital LLC ($245.01K). How much institutional selling is happening at Altamira Therapeutics? Institutional investors have sold a total of 245,010 shares in the last 24 months. This volume of shares sold represents approximately $47.56M in transactions. Related Companies: ALLR Major Shareholders CWBR Major Shareholders MBIO Major Shareholders SLRX Major Shareholders SXTP Major Shareholders CNSP Major Shareholders CLVR Major Shareholders DRMA Major Shareholders NBY Major Shareholders NTBL Major Shareholders This page (NASDAQ:CYTO) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThis 1 Biotech Stock has been shocking the marketsHuge AlertsThings Are Not Normal in America – Here’s What to DoStansberry Research1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altamira Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
